TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3- (2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for α2- and 3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 1, 2006, Pages 410-422

  Atack, John R ^a,b   Wafford, Keith A ^a   Tye, Spencer J ^a   Cook, Susan M ^a   Sohal, Bindi ^a   Pike, Andrew ^a   Sur, Cyrille ^a   Melillo, David ^a   Bristow, Linda ^a   Bromidge, Fran ^a   Ragan, Ian ^a   Kerby, Julie ^a   Street, Les ^a   Carling, Robert ^a   Castro, José L ^a   Whiting, Paul ^a   Dawson, Gerard R ^a   McKernan, Ruth M ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 (1,1 DIMETHYLETHYL) 6 (2 ETHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 3 (2 FLUOROPHENYL) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; ANXIOLYTIC AGENT; PENTETRAZOLE; PYRIDAZINE DERIVATIVE; TPA 023; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; EMOTION; MALE; MONKEY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RODENT; ROTAROD TEST; SEIZURE;

ACOUSTIC STIMULATION; ADRENERGIC ALPHA-AGONISTS; ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; AUTORADIOGRAPHY; CONDITIONING, OPERANT; CONVULSANTS; DRINKING; EMOTIONS; FEAR; FLUMAZENIL; GABA MODULATORS; HUMANS; MALE; MICE; MUSCULOSKELETAL EQUILIBRIUM; PENTYLENETETRAZOLE; PROTEIN BINDING; PYRIDAZINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, GABA-A; RECOMBINANT PROTEINS; SAIMIRI; STARTLE REACTION; SUBSTANCE WITHDRAWAL SYNDROME; TRIAZOLES;

EID: 29244437830     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.089920     Document Type: Article

References (40)

1. Argyropoulos SV and Nutt DJ (1999) The use of benzodiazepines in anxiety and other disorders. Eur Neuropsychopharmacol 9 (Suppl 6):S391-S392.
2. A receptor benzodiazepine binding site. Current Drug Targets CNS Neurol Disorders 2:213-232.
3. A receptors. Br J Pharmacol 144:357-366.
4. A receptors. Neuropsychopharmacology 20:255-262.
5. A receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectr 10:31-39.
6. Bayley P, Bentley GD, Jackson A, Williamson D, and Dawson GR (1996) Comparison of benzodiazepine (BZ) receptor agonists in two rodent activity tests. J Psychopharmacol 10:206-213.
7. A receptors. Br J Pharmacol 136:965-974.
8. A α2/α3-subtype selective agonist which exhibits potent anxiolytic activity but is not sedating in animal models. J Med Chem 48:7089-7092.
9. A α5 receptors with cognition enhancing properties. J Med Chem 47:5829-5832.
10. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
11. A receptor structure relieved by AChBP. Trends Biochem Sci 27:280-287.
12. Dawson GR and Tricklebank MD (1995) Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol Sci 16:33-36.
13. A receptors is sufficient to produce anxiolysis. J Neurosci, in press.
14. Facklam M, Schoch P, Bonetti EP, Jenck F, Martin JR, Moreau J-L, and Haefely WE (1992) Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies. J Pharmacol Exp Ther 261:1113-1121.
15. Foster AC, Pelleymounter MA, Cullen MJ, Lewis D, Joppa M, Chen TK, Bozigian HP, Gross RS, and Gogas KR (2004) In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic. J Pharmacol Exp Ther 311:547-559.
16. Griebel G, Perrault G, Tan S, Schoemaker H, and Sanger DJ (1999) Comparison of the pharmacological properties of classical and novel BZ-ω receptor ligands. Behav Pharmacol 10:483-495.
17. Hadingham KL, Garrett EM, Wafford KA, Bain C, Heavens RP, Sirinathsinghji DJS, and Whiting PJ (1996) Cloning of cDNAs encoding the human γ-aminobutyric acid type A receptor α6 subunit and characterization of the pharmacology of α6-containing receptors. Mol Pharmacol 49:253-259.
18. A receptors. Mol Pharmacol 43:970-975.
19. Haefely W, Martin JR, and Schoch P (1990) Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci 11:452-456.
20. Johnstone TBC, Hogenkamp DJ, Coyne L, Su J, Halliwell RF, Tran MB, Yoshimura RF, Li W-Y, Wang J, and Gee KW (2004) Modifying quinolone antibiotics yields new anxiolytics. Nat Med 10:31-32.
21. Kehne JH, Cassella JV, and DavisM(1988) Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm. Psychopharmacology (Berl) 94:8-13.
22. Löw K, Crestani F, Keist R, Benke D, Brünig I, Benson JA, Fritschy J-M, Rülicke T, Bluethmann H, Möhler H, and Rudolph U (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science (Wash DC) 290:131-134.
23. Martin JR, Jenck F, and Moreau J-L (1995) Comparison of benzodiazepine receptor ligands with partial agonistic, antagonistic or partial inverse agonistic properties in precipitating withdrawal in squirrel monkeys. J Pharmacol Exp Ther 275:405-411.
24. Martin JR, Moreau J-L, Jenck F, and Pieri L (1998) Sarmazenil- precipitated withdrawal: a reliable method for assessing dependence liability of benzodiazepine receptor ligands. Pharmacol Biochem Behav 59:939-944.
25. A receptor α1 subtype. Nat Neurosci 3:587-592.
26. A-receptor subtypes really occur in the brain? Trends Neurosci 19:139-143.
27. Minier F and Sigel E (2004) Techniques: use of concatenated subunits for the study of ligand-gated ion channels. Trends Pharmacol Sci 25:499-503.
28. A receptors. Trends Neurosci 27:569-575.
29. A receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc Natl Acad Sci USA 102:915-920.
30. A receptor subtypes. Nature (Lond) 401:796-800.
31. A receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu Rev Pharmacol Toxicol 44:475-498.
32. Sanger DJ and Depoortere H (1998) The pharmacology and mechanism of action of zolpidem. CNS Drug Rev 4:323-340.
33. A receptor subtype selective benzodiazepine site ligand L-838417. Biopharm Drug Dispos 26:13-20.
34. A receptor subtypes. Pharmacol Rev 47:181-234.
35. A receptor subtypes. Curr Top Med Chem 2:795-816.
36. A receptor genes in the human genome. J Biol Chem 279:41422-41435.
37. van Steveninck AL, Gieschke R, Schoemaker RC, Roncari G, Tuk B, Pieters MS, Breimer DD, and Cohen AF (1996) Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol 41:565-573.
38. A receptors containing the α4 subunit. Mol Pharmacol 50:670-678.
39. A receptors is essential for benzodiazepine agonist binding. J Biol Chem 267:1426-1429.
40. Woods JH and Winger G (1995) Current benzodiazepine issues. Psychopharmacology (Berl) 118:107-115.